

2024 Annual Meeting

12 November 2024

Bali, Indonesia



Agenda

10:30 – 10:45

● **Welcome: Update on WGNV activities and TB Vax ARM**

10:45 – 11:10

● **Key outcomes from the 7th Global Forum on TB Vaccines**

11:10 – 11:50

● **Updates on Phase 3 candidates MTBVAC and M72/AS01E**

11:50 – 12:25

● **Implementation and community engagement**

12:25 – 12:30

● **Closing**

WGNV Year in Review and Year Ahead

Jennifer Woolley and Carly Young

Overarching accomplishments

- Held an open election for two new community representatives to the WGNV Core Group – Peter Owiti Ngo’la(Kenya) and Roger Paul Kamugasha (Uganda)
- Maintained an internship program to give experience and opportunities to graduate-level students from a high burden countries
- Sent periodic emails with updates and opportunities to WGNV members and email subscribers and maintained an active presence on social media
- Refreshed our branding and website

STOP TB PARTNERSHIP WORKING GROUP ON NEW TB VACCINES

ABOUT US | OUR PRIORITIES | TB VACCINE PIPELINE | RESOURCES | OPPORTUNITIES | GET INVOLVED

ENDORSE THE #WINS4TBVAX [Learn More](#)

THE WORKING GROUP ON NEW TB VACCINES

New vaccines are essential to ending the tuberculosis (TB) pandemic. The Stop TB Partnership Working Group on New TB Vaccines (WGNV) helps to facilitate the development of new, more effective TB vaccines by promoting consensus, scientific exchange, and advocacy in support of TB research and development (R&D).

[About the WGNV](#)

THE WORLD URGENTLY NEEDS NEW TB VACCINES

TB remains a major global health threat. In 2022, an estimated 10.6 million people became sick with TB and 1.3 million people died from TB.

The only licensed vaccine to prevent TB – the 100-year old BCG vaccine – provides moderate, although important, protection against severe TB in infants and young children, but it does not adequately protect adolescents and adults, who are most at risk for developing and spreading TB.

Almost 90% of people with TB disease are adolescents and adults



OUR PRIORITIES

WGNV seeks to support and facilitate TB vaccine R&D and to advance the vaccine-related objectives in the Global Plan to End TB by conducting activities in the following priority areas:

ADVOCACY

WGNV implements projects and programs that support TB vaccine research literacy among advocates and affected communities, as well as supporting advocacy literacy among researchers. WGNV also engages in global advocacy efforts as a member of the Core Group of the TB Vaccine Advocacy Roadmap (TB VAR).

[Learn more](#) [Take Action](#)

EARLY CAREER RESEARCHERS

WGNV supports an Early Career Researcher (ECR) Network, which coordinates activities to support and engage ECRs. Activities include online and in-person networking opportunities, workshops, Talk to the Experts sessions on relevant topics, and opportunities to raise the visibility of ECRs in the TB vaccine R&D space.

[Learn more](#)

KNOWLEDGE SHARING & FOSTERING DISCUSSION

WGNV shares knowledge and information about TB vaccine R&D and provides a platform for discussion on key issues, concepts, and gaps. Our activities include organizing workshops, compiling a pipeline of TB vaccine candidates in development, convening the Global Forum on TB Vaccines, and sharing resources and information via our website and mailing list.

[Learn more](#)

ISSUES IN PRODUCT DEVELOPMENT

WGNV recognizes the challenges in translating concepts for novel TB vaccines into potential products. To help address this challenge, WGNV provides resources and information on product development and opportunities for technical support and training. We are also developing a platform for researchers to connect with each other and with potential partners and collaborators.

[Learn more](#)

ABOUT NEW TB VACCINES

ABOUT US | OUR PRIORITIES | TB VACCINE PIPELINE | RESOURCES | OPPORTUNITIES | GET INVOLVED

[Background](#)

[Factheets & Graphics](#)

[Reports](#)

[Roadmaps & Frameworks](#)

[Webinars](#)

[Databases](#)

THE WORLD URGENTLY NEEDS NEW TB VACCINES

TB remains a major global health threat. In 2022, an estimated 10.6 million people became sick with TB and 1.3 million people died from TB.

The only licensed vaccine to prevent TB – the 100-year old BCG vaccine – provides moderate, although important, protection against severe TB in infants and young children, but it does not adequately protect adolescents and adults, who are most at risk for developing and spreading TB.

Multiple new TB vaccines that work across all populations and age groups, particularly among adults and adolescents, will be critical to eliminate TB by 2030 and realize the WHO and TB targets.

NEW VACCINES ARE ESSENTIAL TO END TB

Vaccines are one of the most successful and cost-effective public health interventions for reducing and even eliminating deadly infectious diseases. Yet, the only licensed vaccine against TB is the century-old Saccharin-Calcium-Glutamate (BCG). While it provides some important protection against severe forms of TB in infants and young children, BCG is ineffective in adolescents and adults, who are most at risk of developing and spreading TB.

TACKLING DRUG RESISTANT TB


Drug resistant TB (DR-TB) is a key driver of the growing public health threat of antimicrobial resistance (AMR). In 2022, there were an estimated 1.5 million new cases of TB, including 400,000 DR-TB.

New TB vaccines could contribute to efforts to address DR-TB in several ways:

- They are likely to be equally sensitive against DR-TB and drug-sensitive TB, thus reducing incidence and burden of DR-TB.
- By preventing TB disease, vaccines could reduce the need for antibiotics.
- The most effective would be combination with drugs and disease treatment strategies and include the risk of emergence.

Priority Area: Knowledge-Sharing

- Convened the 7th Global Forum on TB Vaccines, 8 – 10 October in Rio de Janeiro, Brazil
- Utilized the WGNV website to share information about resources, publications, and information related to TB vaccine R&D
- Organized the 2nd WGNV Annual Meeting as part of New TB Tools Summit 2024
- Maintained and updated online pipeline of clinical candidates and launched online pipeline of candidates in preclinical development



Priority Area: Fostering Discussion

- Published workshop report with key outcomes from online meeting in October 2023 on evaluating HBC country data needs to support introduction of new TB vaccines for adolescents and adults
- Co-convenor of workshop on strengthening understanding of market and country planning and preparedness for novel TB vaccines for adolescents and adults.
- Preparatory work for an online community platform for WGNV and TB Vax ARM members to be launched in 2025
- Planning for two online workshops (fit-for-purpose animal models and advocacy)

Priority Area: Issues in Product Development

- Maintained dedicated page on WGNV website with resources and information about technical support and consultation services

Check for updates

OPEN ACCESS

EDITED BY
 Patrick K. Moonan,
 Centers for Disease Control and Prevention
 (CDC), United States

REVIEWED BY
 Jennifer Harris,
 Centers for Disease Control and Prevention
 (CDC), United States
 Soemir Ahmadnoy,
 United States Agency for International
 Development, United States

*CORRESPONDENCE
 Rebecca A. Clark
 ✉ Rebecca.Clark@nhs.uk

[†]These authors share first authorship
[‡]These authors share senior authorship

RECEIVED 08 February 2024
 ACCEPTED 29 March 2024
 PUBLISHED 29 April 2024

CITATION
 Clark RA, Young C, Palmer S, Auma C,
 Malhotra S, Limaye R, Giersing B, Schragar L,
 Voss C, Tiemersma F, Frick M, Edoka I,
 Dagnev F, Nkhoma T, TB Vaccine Country

Bridging the gap: evaluating high TB burden country data needs to support the potential introduction of TB vaccines for adolescents and adults: a workshop report


Rebecca A. Clark^{1,2,3,4*}, Carly Young^{5†}, Shaun Palmer^{6,7†}, Erick Auma^{7,8†}, Shelly Malhotra⁹, Rupali Limaye¹⁰, Birgitte Giersing¹¹, Lewis Schragar⁹, Gerald Voss¹², Edine Tiemersma¹³, Mike Frick¹⁴, Ijeoma Edoka^{15,16}, Alemnew F. Dagnev¹⁷, Thokozile Nkhoma¹⁸, TB Vaccine Country Data Needs Group, Puck T. Pelzer^{5,7,13†} and Richard G. White^{1,2,3,4†}

¹TB Modelling Group and TB Centre, London School of Hygiene and Tropical Medicine, London, United Kingdom, ²Centre for the Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom, ³Department of Infectious Disease



Priority Area: Advocacy

- Supported the Stop TB Partnership Secretariat in planning a session on Vaccines at the February 2024 Board meeting
- Added a dedicated space on the WGNV website for advocacy resources and for community engagement and research literacy and a Take Action center.
- Translated subtitles for videos from the vaccines module of the TB Research online curriculum into four additional languages (French, Spanish, Russian, Brazilian Portuguese) and placed on the WGNV website



Video subtitles in English, Spanish, French, Brazilian Portuguese, and Russian

Priority Area: Early Career Researcher (ECR) Network

Who are we? An informal group that connects and empowers ECRs in TB vaccine R&D: offering resources, support and networking opportunities, and fostering collaboration, knowledge sharing, and professional growth led by an ECR-driven Steering Committee.

2024 Recap

- **Virtual Coffee Corner event**
- **Steering committee elections**

7th Global Forum:

- Networking lunches with senior researchers
- ECR Networking Zone

2025 Outlook

Community Platform Launch: Jan 2025

- Interactive conversational engagement
- Mix technical insights & personal growth topics

“Talk to the experts” Series: speakers/dates TBD

- 5 in-depth discussions on “hot topics” and clinical pipeline challenges in the field
- Key topics: Recap of 7GF & Union, CHIM, including key populations in clinical trials, “subclinical” TB, “latency”

Looking ahead to 2025

- Publish meeting report from 7th Global Forum on TB Vaccines; initiate planning for 8th Global Forum
- Add new online capacity-building tools around research literacy, advocacy/communications literacy, and product development
- Launch online community platform to allow for real-time engagement among WGNV members
- Hold two online workshops to foster discussion on key topics (fit for purpose animal models, other topic to be determined)
- And more.... .sign up for updates!

Learn more and get involved!

Visit our website, review resources, and learn about opportunities to take action 

<https://newtbvaccines.org>

Become a member of the WGNV  <https://newtbvaccines.org/join>

Subscribe to email updates  <https://newtbvaccines.org/subscribe>


**Members will receive emails and do not need to sign up for them*

Email us  wgnv@iavi.org

Follow us  @newtbvaccines



Stop TB Partnership Working Group on New TB Vaccines



TB Vaccine Advocacy Roadmap (TB Vax ARM)


Shaun Palmer



TB VAX ARM

TB Vaccine Advocacy Roadmap

Formed in 2021, the TB Vax ARM is the first globally coordinated advocacy coalition committed to advancing TB vaccine research and development. The network, selected as a WHO TB civil society best practice, includes affected community, civil society, nonprofit, and research representatives, with over 260 members from more than 50 countries. The TB Vax ARM leads collaborative, global advocacy initiatives aligned with ongoing research and policy efforts.



Our approach

The core group conducts activities across four complementary areas:

- **Convening** (webinars, regular meetings, conferences)
- **Analysis** (policy briefs)
- **Advocacy** (campaigns, targeted bilateral engagement with decision makers, civil society input to consultations)
- **Capacity building** (research literacy, fellowships)

Snapshot of activities

Advocacy

Informed the vaccine commitments at the 2023 TB UN High-Level Meeting (HLM), including via an open letter campaign to member states endorsed by almost 1200 signatories from 90 countries



Capacity strengthening

Two online fellowships with community members, advocates, and early career researchers from high burden countries, with the 2023 cohort developing the HLM open letter campaign

Coordinated the 7th Global Forum Community Engagement Committee and Community Declaration

IT'S TIME TO SECURE A HEALTHIER TOMORROW INVEST IN TB VACCINE R&D




Participants of the 2023 TB Vaccine Advocacy Fellowship

Policy briefs

- Two T20 policy briefs proposing recommendations to enhance G20 leadership in TB vaccines through joint, sustained, scaled up investments in research and access
- Policy brief on the need for new TB vaccines to AMR



Learn more



2023 brief




bit.ly/tbvaT20_23



2024 brief



bit.ly/tbvaT20_24



Three wins to deliver new TB vaccines this decade



Measurable increases in national and joint, multilateral funding and financing for TB vaccine R&D



Explicit and transparent commitments and plans from developers and governments to ensure equitable access



TB vaccines and TB R&D integrated into AMR and other relevant global health agendas

TB VAX ARM



Endorse the wins at bit.ly/Wins4TBvax



You can also find translations, access social media materials, and learn what the TB Vax ARM is planning and how you can get involved!



What does the TB Vax ARM plan to do?

- **Develop** resources, campaigns, and policy briefs
- **Liase** with representatives of relevant bodies and institutions, including through letter, consultations, and meetings
- **Collaborate** with civil society and community members advocating to key global agencies
- **Support** the development of a benchmark assessment for vaccine access plans
- **Increase** TB vaccine literacy and demand generation efforts

Endorse the wins at bit.ly/Wins4TBvax

What can you do?

- **Find out** what your country is doing to support global health R&D
- **Reach out** to decision makers in your country to learn how they are supporting TB vaccine development and ask them to meet your country's fair share target
- **Amplify, share, and adapt** TB vaccine advocacy resources in your local contexts and online to raise awareness and work with other organizations
- **Subscribe** to the [TB Vax ARM mailing list](#) to stay up to date
- **Let us know** if you'd like to support us with a specific action – email spalmer@iavi.org

Don't miss TB vaccines at Community Connect

[CCSA007]

[Auditorium]

Driving innovation in TB vaccine advocacy, policy, & access to End TB: An interactive community & civil society discussion

Wed 13 Nov | 4:30 PM – 5:30 PM

TB  AX ARM



bit.ly/UnionCCTBVaxA



[CCSS011]

[Singaraja]

Innovative models to bring new TB tools from the clinic to communities: The role of Product Development Partnerships

Thu 14 Nov | 9:00 AM – 10:00 AM



TB Alliance FIND 



bit.ly/UnionCCpdp

TB AX ARM

TB Vaccine Advocacy Roadmap



Subscribe at newtbvaccines.org/join-tbvaxarm/
or email Shaun Palmer at spalmer@iavi.org